188 related articles for article (PubMed ID: 28851345)
1. Ethical acceptability of offering financial incentives for taking antipsychotic depot medication: patients' and clinicians' perspectives after a 12-month randomized controlled trial.
Noordraven EL; Schermer MHN; Blanken P; Mulder CL; Wierdsma AI
BMC Psychiatry; 2017 Aug; 17(1):313. PubMed ID: 28851345
[TBL] [Abstract][Full Text] [Related]
2. The effect of financial incentives on patients' motivation for treatment: results of "Money for Medication," a randomised controlled trial.
Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AFT; Mulder CL
BMC Psychiatry; 2018 May; 18(1):144. PubMed ID: 29793451
[TBL] [Abstract][Full Text] [Related]
3. Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial.
Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AF; Staring AB; Mulder CL
Lancet Psychiatry; 2017 Mar; 4(3):199-207. PubMed ID: 28236956
[TBL] [Abstract][Full Text] [Related]
4. Money for medication: a randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with psychotic disorders.
Noordraven EL; Audier CH; Staring AB; Wierdsma AI; Blanken P; van der Hoorn BE; Roijen LH; Mulder CL
BMC Psychiatry; 2014 Dec; 14():343. PubMed ID: 25438877
[TBL] [Abstract][Full Text] [Related]
5. Financial incentives to improve adherence to antipsychotic maintenance medication in non-adherent patients: a cluster randomised controlled trial.
Priebe S; Bremner SA; Lauber C; Henderson C; Burns T
Health Technol Assess; 2016 Sep; 20(70):1-122. PubMed ID: 27682868
[TBL] [Abstract][Full Text] [Related]
6. Financial incentives to improve adherence to anti-psychotic maintenance medication in non-adherent patients - a cluster randomised controlled trial (FIAT).
Priebe S; Burton A; Ashby D; Ashcroft R; Burns T; David A; Eldridge S; Firn M; Knapp M; McCabe R
BMC Psychiatry; 2009 Sep; 9():61. PubMed ID: 19785727
[TBL] [Abstract][Full Text] [Related]
7. Financial incentives to improve adherence to medication in five patients with schizophrenia in the Netherlands.
Staring AB; Mulder CL; Priebe S
Psychopharmacol Bull; 2010; 43(1):5-10. PubMed ID: 20581796
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Financial Incentives to Promote Adherence to Depot Antipsychotic Medication: Economic Evaluation of a Cluster-Randomised Controlled Trial.
Henderson C; Knapp M; Yeeles K; Bremner S; Eldridge S; David AS; O'Connell N; Burns T; Priebe S
PLoS One; 2015; 10(10):e0138816. PubMed ID: 26448540
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of financial incentives to improve adherence to maintenance treatment with antipsychotics: cluster randomised controlled trial.
Priebe S; Yeeles K; Bremner S; Lauber C; Eldridge S; Ashby D; David AS; O'Connell N; Forrest A; Burns T
BMJ; 2013 Oct; 347():f5847. PubMed ID: 24100934
[TBL] [Abstract][Full Text] [Related]
10. Medical and social costs after using financial incentives to improve medication adherence: results of a 1 year randomised controlled trial.
Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AFT; Mulder CL
BMC Res Notes; 2018 Sep; 11(1):655. PubMed ID: 30201054
[TBL] [Abstract][Full Text] [Related]
11. Offering financial incentives to increase adherence to antipsychotic medication: the clinician experience.
Highton-Williamson E; Barnicot K; Kareem T; Priebe S
J Clin Psychopharmacol; 2015 Apr; 35(2):120-7. PubMed ID: 25692797
[TBL] [Abstract][Full Text] [Related]
12. The effect of financial incentives on adherence to antipsychotic depot medication: does it change over time?
Pavlickova H; Bremner SA; Priebe S
J Clin Psychiatry; 2015 Aug; 76(8):e1029-34. PubMed ID: 26335089
[TBL] [Abstract][Full Text] [Related]
13. Financial incentives for antipsychotic depot medication: ethical issues.
Claassen D
J Med Ethics; 2007 Apr; 33(4):189-93. PubMed ID: 17400613
[TBL] [Abstract][Full Text] [Related]
14. Better quality of life in patients offered financial incentives for taking anti-psychotic medication: Linked to improved adherence or more money?
Moran K; Priebe S
Qual Life Res; 2016 Aug; 25(8):1897-902. PubMed ID: 26850023
[TBL] [Abstract][Full Text] [Related]
15. A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral.
Patel MX; de Zoysa N; Bernadt M; David AS
J Clin Psychiatry; 2008 Oct; 69(10):1548-56. PubMed ID: 19192437
[TBL] [Abstract][Full Text] [Related]
16. Attitudes of psychiatrists toward antipsychotic depot medication.
Heres S; Hamann J; Kissling W; Leucht S
J Clin Psychiatry; 2006 Dec; 67(12):1948-53. PubMed ID: 17194274
[TBL] [Abstract][Full Text] [Related]
17. [Payment for accepting depot medication].
Mulder CL; Noordraven E; Staring AB
Ned Tijdschr Geneeskd; 2014; 158(4):A7309. PubMed ID: 24447676
[TBL] [Abstract][Full Text] [Related]
18. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.
Godleski LS; Goldsmith LJ; Vieweg WV; Zettwoch NC; Stikovac DM; Lewis SJ
J Clin Psychiatry; 2003 Feb; 64(2):119-22. PubMed ID: 12633119
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients.
Ascher-Svanum H; Peng X; Faries D; Montgomery W; Haddad PM
BMC Psychiatry; 2009 Jul; 9():46. PubMed ID: 19640279
[TBL] [Abstract][Full Text] [Related]
20. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
